(Q38519252)

English

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

scientific article published on 04 June 2015

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

1 reference

based on heuristic

inferred from title

James Chih-Hsin Yang

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Lecia V Sequist

2

object named as

Lecia V Sequist

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Sarayut Lucien Geater

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Chun-Ming Tsai

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Martin Schuler

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Nobuyuki Yamamoto

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Sai-Hong I Ou

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Daniel Massey

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Victoria Zazulina

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Yi-Long Wu

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

4 June 2015

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

830-838

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900026-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00026-1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26051236%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38519252&oldid=1535232357"